Objective: To determine if increased levels of oxidative damage are present in the brains of persons with mild cognitive impairment (MCI), a condition that often precedes Alzheimer disease (AD). Methods: The authors assessed the amount of protein carbonyls, thiobarbituric acid-reactive substances (TBARS), and malondialdehyde in the superior and middle temporal gyri (SMTG) and cerebellum of short postmortem interval and longitudinally evaluated normal subjects and those with MCI and early AD. Results: Elevated levels of protein carbonyls ‫,)%52ف(‬ malondialdehyde ‫,)%06ف(‬ and TBARS ‫)%012ف(‬ were observed in the SMTG of individuals with MCI and early AD vs normal control subjects. The elevation in TBARS was associated with the numbers of neuritic but not diffuse plaques. Levels of protein carbonyls increased as delayed verbal memory performance declined. Conclusion: Oxidative damage occurs in the brain of subjects with mild cognitive impairment, suggesting that oxidative damage may be one of the earliest events in the onset and progression of Alzheimer disease.
Abstract-Objective:
To determine if increased levels of oxidative damage are present in the brains of persons with mild cognitive impairment (MCI), a condition that often precedes Alzheimer disease (AD). Methods: The authors assessed the amount of protein carbonyls, thiobarbituric acid-reactive substances (TBARS), and malondialdehyde in the superior and middle temporal gyri (SMTG) and cerebellum of short postmortem interval and longitudinally evaluated normal subjects and those with MCI and early AD. Results: Elevated levels of protein carbonyls ‫,)%52ف(‬ malondialdehyde ‫,)%06ف(‬ and TBARS ‫)%012ف(‬ were observed in the SMTG of individuals with MCI and early AD vs normal control subjects. The elevation in TBARS was associated with the numbers of neuritic but not diffuse plaques. Levels of protein carbonyls increased as delayed verbal memory performance declined. Conclusion: Oxidative damage occurs in the brain of subjects with mild cognitive impairment, suggesting that oxidative damage may be one of the earliest events in the onset and progression of Alzheimer disease. NEUROLOGY 2005; 64:1152 -1156 Oxidative damage is present in a number of neurodegenerative conditions including Alzheimer disease (AD). [1] [2] [3] [4] [5] [6] Evidence for oxidative damage in the AD brain includes the presence of elevated levels of oxidized lipids, nucleic acids, and proteins. [1] [2] [3] [4] [5] [6] While the precise role that increased levels of oxidative damage play in mediating the onset and progression of AD remains controversial, numerous studies support oxidative damage as contributing to the development of AD. For example, studies have demonstrated that increased levels of oxidative damage may be one of the earliest features observed in the onset of AD. 7, 8 Additionally, oxidative damage appears to be highest in brain regions responsible for the cognitive dysfunction found in AD. [1] [2] [3] [4] [5] [6] [7] [8] Oxidative damage is also highest in the brain regions that exhibit the most neuronal degeneration in AD. [1] [2] [3] [4] [5] [6] [7] [8] Addition of oxidative stressors sufficient to mediate neuron death in vitro 9-12 is consistent with increased oxidative damage playing a causal role in the neuron death observed in AD. Despite the advances made by previous studies, the neuron degeneration that is evident even in early AD has made it difficult to determine if the oxidative damage observed in AD is responsible for mediating neuron death, or occurs as a secondary event or epiphenomenon.
Most subjects with mild cognitive impairment (MCI) ultimately progress to AD, suggesting that MCI may be one of the earliest phases in the development of AD. [13] [14] [15] The neuropathologic changes and neuron degeneration in MCI show some overlap with the autopsy findings in older cognitively intact individuals, 16, 17 suggesting that MCI may provide an opportunity to clarify whether increased oxidative damage is an important factor in the pathogenesis of neuron death in AD or a secondary phenomenon.
Methods. The diagnosis of MCI, early AD, or normal cognitive function was defined by clinical-neuropathologic consensus conference. Final diagnosis used National Institute on Aging-Reagan Institute (NIA-Reagan) criteria, of which Consortium to Establish a Registry for AD (CERAD) is a component. 18 All patients in the study were from the University of Kentucky AD Research Center, and were followed longitudinally. Controls and MCI subjects and some of the patients with early AD were from our longitudinally followed normal control group. The clinical criteria used for the diagnosis of MCI were as described previously, 19, 20 and include the following: 1) memory complaint, preferably corroborated by an informant, 2) objective memory impairment for age and education, 3) normal general cognitive function, 4) intact activities of daily living (ADLs), and 5) the subject does not meet criteria for dementia. [19] [20] [21] The clinical criteria for early AD were as follows: 1) a decline in cognitive function from a previous higher level, 2) deficits in one or more areas of cognition in addition to memory, and 3) AD Assessment Scale cognitive scores in the range of 12 to 18, 4) altered ADLs, 5) Clinical Dementia Rating (CDR) score of 0.5 to 1, and 6) clinical evaluation that excluded other causes of dementia. The control subjects had normal mental status test scores and no clinical evidence of cognitive decline. Neuropathologic studies found no substrate for dementia in controls.
Neuropathology. All subjects were evaluated in the same way at autopsy. Multiple neocortical sections, hippocampus, entorhinal cortex, amygdala, basal ganglia, brainstem, and cerebellar sections were stained with H-E, the modified Bielschowsky stain, the Gallyas stain, and alpha-synuclein and beta-amyloid immunostains. Diffuse plaques (DP), neuritic plaques (NP), and neurofibrillary tangles (NFT) were measured in the five most involved areas of four neocortical sections, hippocampal CA1 and subiculum, amygdala and entorhinal cortex. For this study these lesions were measured in the middle temporal gyrus using the modified Bielschowsky stain. Braak staging was determined using the Gallyas and Bielschowsky-stained sections. 22 Analysis of protein oxidation. Protein oxidation in the superior and middle temporal gyri (SMTG) and cerebellum was determined by quantifying the amount of protein carbonyls present in brain as described previously. [23] [24] [25] This assay is based on the detection of protein carbonyl groups derivatized with 2,4-dinitrophenylhydrazine (DNPH), according to manufacturer's instructions (Intergen Purchase, NY). The difference in absorbance between the DNPH-treated and the HCL-treated samples was determined at 366 nm, and the results were expressed as nmol carbonyl groups/mg of protein using the extinction coefficient of 22.0 mmol Ϫ1 cm Ϫ1 for aliphatic hydrazones. For Western blot analysis DNPH derivatized proteins (50 g) were separated on 7.5% SDS-PAGE gels, followed by transfer to nitrocellulose, and detection using polycolonal anti-DNPH antibody.
Analysis of thiobarbituric acid-reactive substances (TBARS). The levels of TBARS were measured as an index of lipid peroxidation as described previously. 26, 27 In brief, 100 g of brain specimen was homogenized in 0.4 mL of ice-cold 10% trichloroacetic acid and centrifuged for 3 minutes at 3,000 g. The resulting supernatant was removed, and 0.2 mL of TBARS reagent (0.335% 2-thiobarbituric acid in 50% glacial acetic acid) was added to each sample and incubated for 30 minutes in a boiling waterbath. The samples were cooled, 400 L of water-saturated butanol was added, and samples were centrifuged for 3 minutes at 3,000 g. An aliquot (100 L) of the upper organic phase was removed and the fluorescence quantified on a fluorescent plate reader. Data are expressed as nanomoles per milligram of protein using malondialdehyde as the standard.
Measurement of malondialdehyde. The amount of maldondialdehyde was measured using a commercially available (Oxford Biomedical Research, Oxford, MI) chromagenic based assay. 28, 29 The assay was conducted according to manufacturer's instructions, using methodologies that allow for the selective analysis of malondialdehyde (hydrochloric acid), in the absence of 4-hydroxyalkenals (methanesulfonic acid).
Statistical analysis. For all comparisons not involving correlation analysis of variance (using diagnostic group as a factor) with follow up, Scheffe's tests were used to compare mean differences in oxidative markers. In this analysis, p Ͻ 0.05 was considered significant. Analysis of association between oxidative markers and DP, NP, NFT, or memory was conducted using Pearson's r correlation coefficient.
Results. Increased levels of protein carbonyls were observed in the SMTG of subjects with MCI and early AD.
In this study, we sought to demonstrate that increased levels of protein oxidation and lipid oxidation are present in the brain of subjects with MCI, consistent with increased oxidative damage being a mediator in the onset and progression of AD. To determine if oxidative damage occurs in MCI, studies were conducted on brain specimens described above from age-and sex-matched MCI, early AD, and control subjects (table). Analysis of protein carbonyl levels in the SMTG revealed that individuals with MCI possessed a significant elevation in protein oxidation vs control subjects ( figure 1A) . Similarly, elevated levels of protein oxidation were observed in the SMTG of individuals with early AD compared to control subjects (see figure  1A) . No significant alteration in protein carbonyls was observed in the cerebellum of MCI or early AD compared to control subjects (see figure 1A) . The increase in protein carbonyls in the SMTG was correlated with reduced delayed memory performance on a word list recall task (r ϭ Ϫ0.50, p Ͻ 0.05; figure 1B) and with the number of NFT in this region (r ϭ 0.41, p ϭ 0.05). No significant correlation between increased protein oxidation and other aspects of memory (immediate recall, learning) or DP/NP counts were observed (data not shown). Western blot analysis revealed that several proteins of different molecular weight underwent increased levels of oxidation in both MCI and early AD subjects ( figure 1C) .
Increased levels of TBARS and malondialdehyde were observed in the SMTG of MCI and early AD subjects. We next quantified TBARS in the SMTG and cerebellum of MCI, early AD, and control subjects. Increased levels of TBARS were present in the SMTG of MCI (p Ͻ 0.05), with a trend for significance in early AD (p ϭ 0.10), vs control subjects ( figure 2A) . No significant alteration in the level of TBARS was observed in the cerebellum of MCI or early AD patients compared to control subjects ( figure 2B) . A principle component of TBARS is lipid peroxidation products, with malondialdehyde being an important lipid peroxidation product formed in the brain. To confirm that the elevation in lipid peroxidation was occurring in MCI and early AD subjects we conducted additional analysis measuring the amount of malondialdehyde present in patients exhibiting increased TBARs. Increased levels of malondialdehyde ‫)%06ف(‬ were observed in the SMTG of both MCI and early AD subjects (figure 3) vs control subjects.
To determine if the increase in TBARS was related to the number of DP, NP, or NFT present in the SMTG, we conducted correlation studies. No correlation between DP number and TBARS was observed (data not shown). A positive correlation between NP number and increased levels of TBARS was observed (r ϭ 0.66, p Ͻ 0.001; figure 4 ). The number of NFT in this region also was associated with elevated levels of TBARS (r ϭ 0.56, p Ͻ 0.01). No correlation between protein oxidation and DP or NP was observed in any experimental group (data not shown). No association between TBARS and any other aspect of the word list memory task was observed (data not shown). No significant association between malondialdehyde and any neuropathologic findings or word list memory task was observed (data not shown).
Discussion. The present study shows that elevated levels of protein carbonyls occur in MCI. Previous studies have suggested that increased oxidative damage occurs in the blood, urine, and CSF in MCI, 30, 31 but have not demonstrated oxidative damage in the brain of subjects with MCI. One study demonstrated a decrease in plasma antioxidant levels in patients with MCI. 30 Additionally, significantly elevated levels of F 2 -isoprostanes have been reported in the urine, plasma, and CSF of patients with MCI. 31 However, studies show that peripheral levels of F 2 -isoprostanes do not correlate with brain levels in AD or in experimental animals. 32, 33 In our study, increased levels of protein oxidation were observed in MCI and early AD. The amount of protein oxidation was more elevated in MCI vs early AD, but this may be influenced by the small sample size of subjects with early AD. This was a somewhat surprising finding because the brain in early AD con-tains more DP, NP, and NFT and higher Braak stages. The increase in protein oxidation was selective for the SMTG and was not present in the cerebellum, a brain region without pathologic alterations in early AD. The importance of our findings is that oxidative changes are present in the premonitory and early phase of AD and do not appear to be an epiphenomenon or secondary to neurodegeneration found in AD.
This suggests that whatever triggers the oxidative cascade might be a part of the deterministic factors for AD. Additionally, these data indicate that there is a significant correlation between increased levels of protein oxidation in the SMTG and a decline in verbal delayed memory. These data suggest that protein oxidation likely plays some role in mediating the decline in cognitive performance observed in AD. Previous studies have provided experimental evidence that increased levels of protein oxidation contribute to age-related declines in cognition. 23, 34, 35 Our data indicate that even in the earliest stages of AD there is an acceleration of this normal age-related increase in protein oxidation in the SMTG. Together, these data highlight the importance of identifying the proteins that possess increased levels of oxidative damage in MCI and early AD, and understand-ing the molecular basis for increased protein oxidation in the earliest stages of AD.
The amount of TBARS was increased in MCI and early AD. The manner in which we analyzed TBARS in the present study preferentially measures lipid peroxidation, 36 but also likely includes other forms of oxidation such as nucleic acid oxidation. Increased nucleic acid oxidation may be a particularly important contributor to elevated TBARS because studies indicate increased RNA oxidation in AD. 37, 38 Because subjects with elevated TBARS also demonstrated increased levels of malondialdehyde, these data strongly indicate the existence of increased lipid peroxidation in the SMTG of MCI and early AD subjects. In contrast to protein oxidation, where MCI cases showed a mean elevation in contrast to early AD and controls, only a trend toward significant increase in TBARS was present in early AD vs MCI. Presumably, this difference is due in part to the more prominent neurodegenerative alterations observed in early AD. In future studies, it will be critical to identify the specific products that are responsible for increased TBARS in MCI and early AD. Identification of this species may contribute to our understanding of what forms of oxidative dam- age may ultimately contribute to the conversion from MCI to early AD. The elevation of protein oxidation, TBARS, and malondialdehyde in MCI subjects to at least the same degree as early AD brain may have implications for our understanding of the potential importance of oxidative damage in AD. For example, these data may indicate that previous studies that used only early AD or late-stage AD brain specimens may have underestimated the amount of oxidative damage that occurs in the progression of AD. In this scenario, increased neuron death and neuropathologic changes in the AD brain actually decrease the detectible levels of protein oxidation and lipid oxidation. In future studies, it will be critical to elucidate if the increase in oxidative damage in the MCI brain can be found in subcellular compartments such as the synapse, and to determine how increased levels of oxidative damage may affect the function of these individual subcellular compartments.
In the present study, there was a correlation between increased age and elevated TBARS (r ϭ 0.58, p ϭ 0.003); however, a partial correlation controlling for age revealed that increased TBARS remained associated with elevated NP (r ϭ 0.41, p ϭ 0.05). These data suggest that there is a potential relationship between increased TBARS and increased NP formation. Previous studies demonstrate that lipid oxidation appears to be an important catalyst for the propagation of beta amyloid (A␤) deposition in rodent models of AD. 39, 40 Additionally, A␤ has been shown to generate free radicals, which might result in the propagation of further lipid oxidation. [39] [40] [41] [42] Together these data indicate that these two pro- cesses, lipid oxidation and elevated A␤ deposition, may lead to a feed forward pathway that results in accelerated oxidative damage and neuritic plaque formation in AD.
This study adds to our knowledge of early events in AD, and underscores that prevention is the key to effectively combating AD. Although oxidative damage is one of the initial events in AD, which is probably of multiple etiologies and pathogeneses, this study shows that it is present early and those at risk could receive neuroprotective therapy such as antioxidants early in life. 
